BMO Capital analyst Etzer Darout initiates coverage on $Protagonist Therapeutics (PTGX.US)$ with a buy rating, and sets the target price at $62.
According to TipRanks data, the analyst has a success rate of 59.6% and a total average return of 37.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Protagonist Therapeutics (PTGX.US)$'s main analysts recently are as follows:
Protagonist Therapeutics' Phase 3 assets are considered to have commercial potential, although they have been licensed which offers 'limited' financial and M&A upside. The substantial over 400% increase in the company's stock price over the past two years can be attributed to development progression and licensing deals, suggesting that the current price already accounts for the anticipated benefits from these assets.
Protagonist Therapeutics is capitalizing on its peptide technology platform to tackle disorders in hematology and immunology. The company's stock is projected to gain in value following significant clinical advancements over the coming year, bolstered by key developments with rusfertide and JNJ-2113. Additionally, Protagonist is poised to offer oral medication alternatives in highly lucrative markets predominantly occupied by injectable therapies.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
BMO资本市场分析师Etzer Darout首予$Protagonist Therapeutics (PTGX.US)$买入评级，目标价62美元。
根据TipRanks数据显示，该分析师近一年总胜率为59.6%，总平均回报率为37.0%。
此外，综合报道，$Protagonist Therapeutics (PTGX.US)$近期主要分析师观点如下：
Protagonist Therapeutics的第三阶段资产被认为具有商业潜力，尽管它们已获得许可，但其财务和并购上行空间 “有限”。在过去两年中，该公司股价大幅上涨了400％以上，这可以归因于开发进展和许可协议，这表明当前的价格已经考虑了这些资产的预期收益。
Protagonist Therapeutics正在利用其肽技术平台来解决血液学和免疫学方面的疾病。在rusfertide和 JNJ-2113 的关键进展的推动下，在来年取得重大临床进展之后，该公司的股票价值预计将上涨。此外，Protagonist准备在主要由注射疗法占据的利润丰厚的市场中提供口服药物替代品。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
